CollPlant’s rhCollagen-Based BioInk Demonstrates Strong Performance in Study

CollPlant Biotechnologies Ltd. announced positive results from a head-to-head comparative study of its rhCollagen-based bioink, Collink.3D™, and Matrigel®, conducted by the Technion - Israel Institute of Technology. The study found that Collink.3D™ outperformed Matrigel®, a leading extracellular matrix, in supporting structured tissue formation. Collink.3D™ demonstrated enhanced mechanical strength, elasticity, and stability, providing a reproducible environment that supports organized and long-lasting tissue formation. The findings suggest that Collink.3D™ could offer a consistent, tunable, and animal-free alternative for advanced tissue engineering and research applications. The global market for basement membrane matrices, including Matrigel and similar products, was valued at approximately $96 million in 2024 and is projected to reach $201 million by 2031, growing at a CAGR of 11.2%.